[go: up one dir, main page]

WO1999026660A3 - Conjugates of cytokines and drugs or genes for treating proliferating cells - Google Patents

Conjugates of cytokines and drugs or genes for treating proliferating cells Download PDF

Info

Publication number
WO1999026660A3
WO1999026660A3 PCT/GB1998/003509 GB9803509W WO9926660A3 WO 1999026660 A3 WO1999026660 A3 WO 1999026660A3 GB 9803509 W GB9803509 W GB 9803509W WO 9926660 A3 WO9926660 A3 WO 9926660A3
Authority
WO
WIPO (PCT)
Prior art keywords
proliferation
active
proliferating cells
drugs
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1998/003509
Other languages
French (fr)
Other versions
WO1999026660A2 (en
Inventor
Christopher Ralph Franks
Bitta Ruggero Della
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOINNOVATION Ltd
Original Assignee
BIOINNOVATION Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOINNOVATION Ltd filed Critical BIOINNOVATION Ltd
Priority to NZ504625A priority Critical patent/NZ504625A/en
Priority to JP2000521861A priority patent/JP2001523731A/en
Priority to AU12499/99A priority patent/AU1249999A/en
Priority to CA002311733A priority patent/CA2311733A1/en
Priority to EP98955771A priority patent/EP1032427A2/en
Publication of WO1999026660A2 publication Critical patent/WO1999026660A2/en
Publication of WO1999026660A3 publication Critical patent/WO1999026660A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A product comprising a proliferatively active moiety, typically a cytokine or growth factor which has a high affinity receptor, linked to a biologically active agent which agent preferentially or selectively affects proliferating cells. An active promoter of proliferation, for example an active IL-2, is beneficially used to deliver pharmacologically desirable species to cells whose proliferation is not desired. For example some medicaments of the invention control or inhibit proliferation using a molecule which contains an active promoter of proliferation. The biologically active agent is usually selected from the group consisting of antiproliferative drugs, compounds which interfere with nucleotide synthesis, radioisotopes, gene sequences and antisense nucleotide sequences.
PCT/GB1998/003509 1997-11-26 1998-11-25 Conjugates of cytokines and drugs or genes for treating proliferating cells Ceased WO1999026660A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NZ504625A NZ504625A (en) 1997-11-26 1998-11-25 Cytokines or growth factors linked to agents which control cell proliferation and pharmaceutical use
JP2000521861A JP2001523731A (en) 1997-11-26 1998-11-25 Proliferatively active products for treating growing cells
AU12499/99A AU1249999A (en) 1997-11-26 1998-11-25 Proliferatively active product for treating proliferating cells
CA002311733A CA2311733A1 (en) 1997-11-26 1998-11-25 Proliferatively active product for treating proliferating cells
EP98955771A EP1032427A2 (en) 1997-11-26 1998-11-25 Conjugates of cytokines and drugs or genes for treating proliferating cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9724838.9A GB9724838D0 (en) 1997-11-26 1997-11-26 Compositions
GB9724838.9 1997-11-26

Publications (2)

Publication Number Publication Date
WO1999026660A2 WO1999026660A2 (en) 1999-06-03
WO1999026660A3 true WO1999026660A3 (en) 1999-10-14

Family

ID=10822573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/003509 Ceased WO1999026660A2 (en) 1997-11-26 1998-11-25 Conjugates of cytokines and drugs or genes for treating proliferating cells

Country Status (8)

Country Link
EP (1) EP1032427A2 (en)
JP (1) JP2001523731A (en)
AU (1) AU1249999A (en)
CA (1) CA2311733A1 (en)
GB (1) GB9724838D0 (en)
NZ (1) NZ504625A (en)
WO (1) WO1999026660A2 (en)
ZA (1) ZA9810759B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5088600A (en) * 1999-06-03 2000-12-28 Bioinnovation Limited Gene therapy products
US7196093B2 (en) 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US7868011B2 (en) 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
BR112013023151A2 (en) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleukin-2 for use in the treatment of autoimmune, immune-related or inflammatory disorder and method for determining whether a regimen or dose of il-2 needs to be modified
CN103732241A (en) 2011-03-11 2014-04-16 公共事业救济局-巴黎医院 Use of low-dose IL-2 for the treatment of autoimmune-related or inflammatory disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318948A2 (en) * 1987-12-02 1989-06-07 Neorx Corporation Cleavable immunoconjugates for the delivery and release of agents in native form
EP0398305A2 (en) * 1989-05-17 1990-11-22 Bristol-Myers Squibb Company Anthracycline conjugates having a novel linker and methods for their production
EP0510949A2 (en) * 1991-04-23 1992-10-28 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
WO1993006847A1 (en) * 1991-10-07 1993-04-15 Genentech, Inc. Use of ifn-gamma for the treatment of infections in transplant recipients
EP0624377A2 (en) * 1993-05-14 1994-11-17 Bristol-Myers Squibb Company Lysosomal enzyme-cleavable antitumor drug conjugates
WO1995027732A2 (en) * 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Circularly permuted ligands and circularly permuted chimeric molecules

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318948A2 (en) * 1987-12-02 1989-06-07 Neorx Corporation Cleavable immunoconjugates for the delivery and release of agents in native form
EP0398305A2 (en) * 1989-05-17 1990-11-22 Bristol-Myers Squibb Company Anthracycline conjugates having a novel linker and methods for their production
EP0510949A2 (en) * 1991-04-23 1992-10-28 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
WO1993006847A1 (en) * 1991-10-07 1993-04-15 Genentech, Inc. Use of ifn-gamma for the treatment of infections in transplant recipients
EP0624377A2 (en) * 1993-05-14 1994-11-17 Bristol-Myers Squibb Company Lysosomal enzyme-cleavable antitumor drug conjugates
WO1995027732A2 (en) * 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Circularly permuted ligands and circularly permuted chimeric molecules

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BUKOWSKI R. M.: "Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2", CANCER, vol. 80, no. 7, 1 October 1997 (1997-10-01), pages 1198 - 1220, XP002097613 *
KONIGSBERG PJ ET AL: "The development of IL-2 conjugated liposomes for therapeutic purposes.", BIOCHIM BIOPHYS ACTA, MAR 13 1998, 1370 (2) P243-51, NETHERLANDS, XP002110538 *
MATOS DA SILVA A. C. ET AL: "Outpatient therapy with aldesleukin after autologous bone marrow transplantation", AM J. HEALTH-SYST PHARM, vol. 53, 15 July 1996 (1996-07-15), pages 1722 - 1727, XP002097614 *
Proleukin (aldesleukin) CHIRON. January 1998 Prescribing information (United States) *
SUNDIN D. J. ET AL: "Aldesleukin therapy in HIV infected patients", AM J. HEALTH-SYST PHARM, vol. 55, 15 July 1998 (1998-07-15), pages 1520 - 1523, XP002097615 *
SUTHERLAND F. ET AL: "Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporin", CANCER IMMUNOL IMMUNOTHER, vol. 31, 1990, pages 312 - 320, XP002097616 *

Also Published As

Publication number Publication date
CA2311733A1 (en) 1999-06-03
WO1999026660A2 (en) 1999-06-03
EP1032427A2 (en) 2000-09-06
AU1249999A (en) 1999-06-15
ZA9810759B (en) 2000-05-25
NZ504625A (en) 2002-12-20
JP2001523731A (en) 2001-11-27
GB9724838D0 (en) 1998-01-21

Similar Documents

Publication Publication Date Title
Ye et al. Cellular and molecular mechanisms of IFN‐γ production induced by IL‐2 and IL‐12 in a human NK cell line
ZA96503B (en) Stable-lipid-comprising drug delivery complexes and methods for their production
US7667027B2 (en) Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β)
HUP9801216A2 (en) Dna molecules, preparation thereof and use thereof in gene therapy
AU7585498A (en) Inhibition of p38 kinase activity by aryl ureas
AU5121399A (en) Rna targeted 2'-modified oligonucleotides that are conformationally preorganized
ATE309345T1 (en) ANTITUMOR ANTISENSE SEQUENCES AGAINST H1 AND R2 COMPOUNDS OF RIBONUCLEOTIDE REDUCTASE
EP2058327A3 (en) Genes encoding insect odorant receptors and uses thereof
IL121421A0 (en) Oligonucleoside sequences of from about 6 to about 200 bases having a three atom internucleoside linkage and pharmaceutical compositions for inhibiting gene expression containing said oligonucleosides
CA2088258A1 (en) Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
WO1999026660A3 (en) Conjugates of cytokines and drugs or genes for treating proliferating cells
AU2647495A (en) Novel potent inducers of terminal differentiation and methods of use thereof
JPH09506770A (en) Antisense nucleic acid for preventing and treating diseases associated with the expression of c-erbB
EP0848061A3 (en) Self-enhancing, pharmacologically controllable expression systems
PT1043995E (en) Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
AU8088694A (en) 2'-amido and 2'-peptido modified oligonucleotides
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
IL128769A0 (en) Expression of an exogenous gene by us of a non-mammalian dna virus
EP2028274A3 (en) An antisense oligonucleotide against the TGF-beta2 gene
WO2001026629A3 (en) Neutral-cationic lipid for nucleic acid and drug delivery
AU3295700A (en) Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
DK0426521T3 (en) Use of interleukin 2 for the treatment of leukemia
AU4848793A (en) Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
WO1999058656A3 (en) Sustained dna delivery from structural matrices
Grunicke et al. Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 12499/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 504625

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2311733

Country of ref document: CA

Ref country code: CA

Ref document number: 2311733

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998955771

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998955771

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998955771

Country of ref document: EP